PD08-08 TRIFECTA OUTCOMES AFTER PERCUTANEOUS RENAL MASS ABLATION: ANALYSIS OF 234 CASES WITH 3.5 YEARS MEDIAN FOLLOW-UP

You have accessJournal of UrologyKidney Cancer: Localized: Ablative Therapy (PD08)1 Apr 2020PD08-08 TRIFECTA OUTCOMES AFTER PERCUTANEOUS RENAL MASS ABLATION: ANALYSIS OF 234 CASES WITH 3.5 YEARS MEDIAN FOLLOW-UP Naveen Nandanan*, Ugo Falagario, Fady Ghali, Alessandro Veccia, Gerant Rivera-Sanfeliz, Ahmed Eldefrawy, Syed Reza, Kunal Patel, Ithaar Derweesh, and Riccardo Autorino Naveen Nandanan*Naveen Nandanan* More articles by this author , Ugo FalagarioUgo Falagario More articles by this author , Fady GhaliFady Ghali More articles by this author , Alessandro VecciaAlessandro Veccia More articles by this author , Gerant Rivera-SanfelizGerant Rivera-Sanfeliz More articles by this author , Ahmed EldefrawyAhmed Eldefrawy More articles by this author , Syed RezaSyed Reza More articles by this author , Kunal PatelKunal Patel More articles by this author , Ithaar DerweeshIthaar Derweesh More articles by this author , and Riccardo AutorinoRiccardo Autorino More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000000835.08AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Cancer control, minimal complications and preservation of kidney function are all desirable outcomes of any procedure performed in patients with renal mass. Herein we introduce a “Trifecta” outcome for patients undergoing percutaneous kidney ablation (PKA) and evaluate this parameter in a contemporary multicenter series. METHODS: We identified 234 patients who underwent PKA at two large academic institutions in the US. Trifecta was defined as absence of perioperative complications, no significant eGFR reduction (>25% reduction from baseline eGFR), and no evidence of disease (recurrence, metastasis, survival). The incidence of significant eGFR reduction and recurrence was estimated using the Kaplan-Meier method. Univariate and multivariate analysis were used to identify predictors of Trifecta achievement. RESULTS: Preoperative characteristics of the study population are shown in table 1. Tumor stage was T1a in 216 (92.3%) and T1b in 18 (7.7%). Median follow-up was 42.4 months. Trifecta was achieved in 142 patients (60.7%). Overall 59 patients (25.2%) developed significant eGFR reduction and 28 patients (12.0%) developed recurrence that was managed successfully with repeat ablation in 11 patients and subsequent surgery in 14 patients. 3 patients did not undergo additional treatment. Complications occurred in 21 patients (9%). The most frequent complications were small subcapsular hematomas and hematuria. Only one patient required embolization for right intra-lobar artery hemorrhage. At univariate analysis, gender (OR 0.30), race (OR 0.58), baseline eGFR (OR 0.99), tumor size (OR 0.65) and tumor stage (OR 0.29) emerged as predictors of trifecta achievement. Gender, baseline eGFR and tumor size also remained significant at the multivariable analysis. CONCLUSIONS: Our findings confirm that PKA represents a safe and effective treatment option in patients with renal mass. Tumor size, baseline eGFR and gender seem to be strong predictors of Trifecta outcomes, and they should be considered when determining treatment plan. Source of Funding: None © 2020 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 203Issue Supplement 4April 2020Page: e170-e171 Advertisement Copyright & Permissions© 2020 by American Urological Association Education and Research, Inc.MetricsAuthor Information Naveen Nandanan* More articles by this author Ugo Falagario More articles by this author Fady Ghali More articles by this author Alessandro Veccia More articles by this author Gerant Rivera-Sanfeliz More articles by this author Ahmed Eldefrawy More articles by this author Syed Reza More articles by this author Kunal Patel More articles by this author Ithaar Derweesh More articles by this author Riccardo Autorino More articles by this author Expand All Advertisement PDF downloadLoading ...